Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Hao

Showing results (571-580 of 584) with videos related to

Pageof 59
Sort By:
Nature Medicine|May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Jihong Liu, Jing Wang, et al.
JAMA Oncology|July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical TrialNing Li, Jianqing Zhu, Rutie Yin, et al.
Nature Communications|June 11, 2026
TaMPK3 mediates synergistic damage from Fusarium crown rot and drought in wheatLei Zheng, Tai-Fei Yu, Ying Liu, et al.
Eclinicalmedicine|May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Jianqing Zhu, Rutie Yin, et al.
JCI Insight|May 22, 2024
Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibodyYi-Hsuan Chang, Min-Feng Hsu, Wei-Nan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III TrialNing Li, Youzhong Zhang, Jing Wang, et al.
Chinese Medical Journal|November 15, 2017
Proportion of Uterine Malignant Tumors in Patients with Laparoscopic Myomectomy: A National Multicenter Study in ChinaHua Yang, Xiao-Chuan Li, Chen Yao, et al.
Plos Genetics|November 21, 2012
Genome, functional gene annotation, and nuclear transformation of the heterokont oleaginous alga Nannochloropsis oceanica CCMP1779Astrid Vieler, Guangxi Wu, Chia-Hong Tsai, et al.
Plos Genetics|May 26, 2017
Correction: Genome, Functional Gene Annotation, and Nuclear Transformation of the Heterokont Oleaginous Alga Nannochloropsis oceanica CCMP1779Astrid Vieler, Guangxi Wu, Chia-Hong Tsai, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 59

Showing results (571-580 of 584) with videos related to

Sort By:
Pageof 59
Nature Medicine|May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Jihong Liu, Jing Wang, et al.
JAMA Oncology|July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical TrialNing Li, Jianqing Zhu, Rutie Yin, et al.
Nature Communications|June 11, 2026
TaMPK3 mediates synergistic damage from Fusarium crown rot and drought in wheatLei Zheng, Tai-Fei Yu, Ying Liu, et al.
Eclinicalmedicine|May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Jianqing Zhu, Rutie Yin, et al.
JCI Insight|May 22, 2024
Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibodyYi-Hsuan Chang, Min-Feng Hsu, Wei-Nan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III TrialNing Li, Youzhong Zhang, Jing Wang, et al.
Chinese Medical Journal|November 15, 2017
Proportion of Uterine Malignant Tumors in Patients with Laparoscopic Myomectomy: A National Multicenter Study in ChinaHua Yang, Xiao-Chuan Li, Chen Yao, et al.
Plos Genetics|November 21, 2012
Genome, functional gene annotation, and nuclear transformation of the heterokont oleaginous alga Nannochloropsis oceanica CCMP1779Astrid Vieler, Guangxi Wu, Chia-Hong Tsai, et al.
Plos Genetics|May 26, 2017
Correction: Genome, Functional Gene Annotation, and Nuclear Transformation of the Heterokont Oleaginous Alga Nannochloropsis oceanica CCMP1779Astrid Vieler, Guangxi Wu, Chia-Hong Tsai, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 59